Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing

References

• Rahib L , Smith BD , Aizenberg R , et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res . 2014;74:2913–2921. doi:10.1158/0008-5472.CAN-14-0155 24840647
   PubMed Web of Science ®Google Scholar
• Malvezzi M , Bertuccio P , Rosso T , et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol . 2015;26:779–786. doi:10.1093/annonc/mdv001 25623049
   PubMed Web of Science ®Google Scholar
• Balachandran VP , Beatty GL , Dougan SK . Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology . 2019;156:2056–2072. doi:10.1053/j.gastro.2018.12.038 30660727
   PubMed Web of Science ®Google Scholar
• Neesse A , Bauer CA , Ohlund D , et al. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Gut . 2019;68:159–171. doi:10.1136/gutjnl-2018-316451 30177543
   PubMed Web of Science ®Google Scholar
• Singhi AD , Koay EJ , Chari ST , et al. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology . 2019;156:2024–2040. doi:10.1053/j.gastro.2019.01.259 30721664
   PubMed Web of Science ®Google Scholar
• Kleeff J , Korc M , Apte M , et al. Pancreatic cancer. Nat Rev Dis Primers . 2016;2:16022. doi:10.1038/nrdp.2016.22 27158978
   PubMed Web of Science ®Google Scholar
• Biankin AV , Waddell N , Kassahn KS , et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature . 2012;491:399–405. doi:10.1038/nature11547 23103869
   PubMed Web of Science ®Google Scholar
• Waddell N , Pajic M , Patch AM , et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature . 2015;518:495–501. doi:10.1038/nature14169 25719666
   PubMed Web of Science ®Google Scholar
• Bailey P , Chang DK , Nones K , et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature . 2016;531:47–52. doi:10.1038/nature16965 26909576
   PubMed Web of Science ®Google Scholar
• Jahr S , Hentze H , Englisch S , et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res . 2001;61:1659–1665.11245480
   PubMed Web of Science ®Google Scholar
• Crowley E , Di Nicolantonio F , Loupakis F , et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol . 2013;10:472–484. doi:10.1038/nrclinonc.2013.110 23836314
   PubMed Web of Science ®Google Scholar
• Li L , Zhang J , Jiang X , et al. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res . 2018;8:1947–1956.30416847
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C , Pantel K . Real-time liquid biopsy: circulating tumor cells versus circulating tumor DNA. Ann Transl Med . 2013;1:18. doi:10.3978/j.issn.2305-5839.2013.06.02 25332962
   PubMedGoogle Scholar
• Murtaza M , Dawson SJ , Tsui DW , et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature . 2013;497:108–112. doi:10.1038/nature12065 23563269
   PubMed Web of Science ®Google Scholar
• Dawson SJ , Tsui DW , Murtaza M , et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med . 2013;368:1199–1209. doi:10.1056/NEJMoa1213261 23484797
   PubMed Web of Science ®Google Scholar
• Aravanis AM , Lee M , Klausner RD . Next-generation sequencing of circulating tumor DNA for early cancer detection. Cell . 2017;168:571–574. doi:10.1016/j.cell.2017.01.030 28187279
   PubMed Web of Science ®Google Scholar
• Madsen AT , Winther-Larsen A , McCulloch T , et al. Genomic profiling of circulating tumor DNA predicts outcome and demonstrates tumor evolution in ALK-positive non-small cell lung cancer patients. Cancers (Basel) . 2020;12. doi:10.3390/cancers12040947
   Web of Science ®Google Scholar
• Kurihara S , Ueda Y , Onitake Y , et al. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg . 2015;50:2094–2097. doi:10.1016/j.jpedsurg.2015.08.033 26388126
   PubMed Web of Science ®Google Scholar
• Ikeda S , Lim JS , Kurzrock R . Analysis of tissue and circulating tumor DNA by next-generation sequencing of hepatocellular carcinoma: implications for targeted therapeutics. Mol Cancer Ther . 2018;17:1114–1122. doi:10.1158/1535-7163.Mct-17-0604 29483209
   PubMed Web of Science ®Google Scholar
• Zill OA , Greene C , Sebisanovic D , et al. Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas. Cancer Discov . 2015;5:1040–1048. doi:10.1158/2159-8290.Cd-15-0274 26109333
   PubMed Web of Science ®Google Scholar
• Kinugasa H , Nouso K , Miyahara K , et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer . 2015;121:2271–2280. doi:10.1002/cncr.29364 25823825
   PubMed Web of Science ®Google Scholar
• Sefrioui D , Blanchard F , Toure E , et al. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer . 2017;117:1017–1025. doi:10.1038/bjc.2017.250 28772284
   PubMed Web of Science ®Google Scholar
• Perdomo Zaldivar E , Inga E , Cano T , et al. K-Ras mutation in liquid biopsy and tumor tissue correlation in patients with pancreatic cancer. Ann Oncol . 2019;30:iv84. doi:10.1093/annonc/mdz155.304
   Web of Science ®Google Scholar
• Wang Z-Y , Ding X-Q , Zhu H , et al. KRAS mutant allele fraction in circulating cell-free DNA correlates with clinical stage in pancreatic cancer patients. Front Oncol . 2019;9. doi:10.3389/fonc.2019.01295
   Web of Science ®Google Scholar
• Patel H , Okamura R , Fanta P , et al. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. J Hematol Oncol . 2019;12:130. doi:10.1186/s13045-019-0824-4 31801585
   PubMed Web of Science ®Google Scholar
• Ako S , Nouso K , Kinugasa H , et al. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Pancreatology . 2017;17:285–290. doi:10.1016/j.pan.2016.12.011 28139399
   PubMed Web of Science ®Google Scholar
• Perets R , Greenberg O , Shentzer T , et al. Mutant KRAS circulating tumor DNA is an accurate tool for pancreatic cancer monitoring. The Oncologist . 2018;23:566–572. doi:10.1634/theoncologist.2017-0467 29371474
   PubMed Web of Science ®Google Scholar
• Pishvaian MJ , Joseph Bender R , Matrisian LM , et al. A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. Oncotarget . 2017;8:83446–83456. doi:10.18632/oncotarget.13225 29137355
   PubMedGoogle Scholar
• Earl J , Garcia-Nieto S , Martinez-Avila JC , et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer . 2015;15:797. doi:10.1186/s12885-015-1779-7 26498594
   PubMed Web of Science ®Google Scholar
• Chen H , Tu H , Meng ZQ , et al. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol . 2010;36:657–662. doi:10.1016/j.ejso.2010.05.014 20542658
   PubMed Web of Science ®Google Scholar
• Le Calvez-kelm F , Foll M , Wozniak MB , et al. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. Oncotarget . 2016;7:78827–78840. doi:10.18632/oncotarget.12386 27705932
   PubMed Web of Science ®Google Scholar
• Takai E , Totoki Y , Nakamura H , et al. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Sci Rep . 2015;5:18425. doi:10.1038/srep18425 26669280
   PubMed Web of Science ®Google Scholar
• Adamo P , Cowley CM , Neal CP , et al. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer. Oncotarget . 2017;8:87221–87233. doi:10.18632/oncotarget.20250 29152076
   PubMedGoogle Scholar
• Hadano N , Murakami Y , Uemura K , et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer . 2016;115:59–65. doi:10.1038/bjc.2016.175 27280632
   PubMed Web of Science ®Google Scholar
• Del Re M , Vivaldi C , Rofi E , et al. Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer. Sci Rep . 2017;7:7931. doi:10.1038/s41598-017-08297-z 28801547
   PubMed Web of Science ®Google Scholar
• Cohen JD , Javed AA , Thoburn C , et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proc Natl Acad Sci U S A . 2017;114:10202–10207. doi:10.1073/pnas.1704961114 28874546
   PubMed Web of Science ®Google Scholar
• Buscail E , Maulat C , Muscari F , et al. Liquid biopsy approach for pancreatic ductal adenocarcinoma. Cancers . 2019;11:852.
   PubMed Web of Science ®Google Scholar
• Wei T , Zhang Q , Li X , et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling circulating cell-free DNA in pancreatic cancer. Mol Cancer Ther . 2019;18:196–203. doi:10.1158/1535-7163.Mct-17-1298 30301865
   PubMed Web of Science ®Google Scholar
• Pietrasz D , Pécuchet N , Garlan F , et al. Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker. Clin Cancer Res . 2017;23:116–123. doi:10.1158/1078-0432.Ccr-16-0806 27993964
   PubMed Web of Science ®Google Scholar
• Cheng H , Liu C , Jiang J , et al. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Int J Cancer . 2017;140:2344–2350. doi:10.1002/ijc.30650 28205231
   PubMed Web of Science ®Google Scholar
• Siravegna G , Mussolin B , Buscarino M , et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med . 2015;21:795–801. doi:10.1038/nm.3870 26030179
   PubMed Web of Science ®Google Scholar
• Pantel K , Alix-Panabieres C . Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol . 2019;16:409–424. doi:10.1038/s41571-019-0187-3 30796368
   PubMed Web of Science ®Google Scholar
• Kilgour E , Rothwell DG , Brady G , et al. Liquid biopsy-based biomarkers of treatment response and resistance. Cancer Cell . 2020;37:485–495. doi:10.1016/j.ccell.2020.03.012 32289272
   PubMed Web of Science ®Google Scholar
• Bettegowda C , Sausen M , Leary RJ , et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med . 2014;6:224ra224–224ra224. doi:10.1126/scitranslmed.3007094
   Web of Science ®Google Scholar
• Kustanovich A , Schwartz R , Peretz T , et al. Life and death of circulating cell-free DNA. Cancer Biol Ther . 2019;20:1057–1067. doi:10.1080/15384047.2019.1598759 30990132
   PubMed Web of Science ®Google Scholar
• Schwarzenbach H , Hoon DS , Pantel K . Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer . 2011;11:426–437. doi:10.1038/nrc3066 21562580
   PubMed Web of Science ®Google Scholar
• Volik S , Alcaide M , Morin RD , et al. Cell-free DNA (cfDNA): clinical Significance and utility in cancer shaped by emerging technologies. Mol Cancer Res . 2016;14:898–908. doi:10.1158/1541-7786.Mcr-16-0044 27422709
   PubMed Web of Science ®Google Scholar
• Postel M , Roosen A , Laurent-Puig P , et al. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn . 2018;18:7–17. doi:10.1080/14737159.2018.1400384 29115895
   PubMed Web of Science ®Google Scholar
• Yang X , Zhuo M , Ye X , et al. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Oncotarget . 2016;7:20810–20824. doi:10.18632/oncotarget.8021 26989078
   PubMedGoogle Scholar
• Kanda M , Matthaei H , Wu J , et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology . 2012;142:730–733.e739. doi:10.1053/j.gastro.2011.12.042 22226782
   PubMed Web of Science ®Google Scholar
• Hruban RH , Wilentz RE , Kern SE . Genetic progression in the pancreatic ducts. Am J Pathol . 2000;156:1821–1825. doi:10.1016/S0002-9440(10)65054-7 10854204
   PubMed Web of Science ®Google Scholar
• Jones S , Zhang X , Parsons DW , et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science . 2008;321:1801–1806. doi:10.1126/science.1164368 18772397
   PubMed Web of Science ®Google Scholar
• Berger AW , Schwerdel D , Ettrich TJ , et al. Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer. Oncotarget . 2018;9:2076–2085. doi:10.18632/oncotarget.23330 29416754
   PubMedGoogle Scholar
• Vidal J , Muinelo L , Dalmases A , et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol . 2017;28:1325–1332. doi:10.1093/annonc/mdx125 28419195
   PubMed Web of Science ®Google Scholar